-
Biocytogen Pharmaceuticals Receives CNIPA Patent for RenMab Human Antibody Mice Platform
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced receiving a prestigious patent award from the China National Intellectual Property Administration (CNIPA) for its in-house developed human antibody mice RenMab platform. This recognition underscores the company’s commitment to innovation in the field of antibody development. RenMab Technology Platform OverviewThe…
-
BeiGene Initiates First-in-Human Trial for Next-Generation BCL-2 Inhibitor BGB-21447
•
China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the first patient dosing in a first-in-human trial for its pipeline candidate, BGB-21447, a next-generation BCL-2 inhibitor. The trial, which is potentially superior to venetoclax based on preclinical activity, is being conducted at Shandong Hospital. Phase I Study Design and…
-
Jiangsu Hengrui Pharmaceutials’ SHR-1209 for Hypercholesterolemia Accepted for NMPA Review
•
China-based Jiangsu Hengrui Pharmaceutials (SHA: 600276) has announced that a market filing for its Category 1 biologic product, SHR-1209, has been accepted for review by the National Medical Products Administration (NMPA). The product is intended to treat hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. Phase…
-
Minghui Pharmaceutical Achieves First Dosing Milestone in Phase I Studies for ADC Candidates
•
China-based biotech Minghui Pharmaceutical Inc. has reported that the first dosing has been completed in two Phase I studies assessing the company’s antibody drug conjugate (ADC) candidate drugs, MHB036C and MHB088C. Both candidates are developed on Minghui’s proprietary SuperTopoi platform, with MHB036C targeting TROP2 and MHB088C targeting B7-H3. SuperTopoi Platform…
-
Xiamen ITG Group and Fosun Health Collaborate on Big Health Industry Fund and Medical Device Commercialization
•
China-based Xiamen ITG Group Co., Ltd. (SHA: 600755) and Shanghai Fosun Health Technology (Group) Co., Ltd have announced a strategic partnership to establish a big health industry fund, collaborate on the commercialization of medical devices, and explore the development and application of health big data. While financial details of the…
-
Australian Scleral Lens Epicon A Approved by China’s NMPA as 10th Novel Product
•
Ruitai Bio’s Epicon A, a scleral lens product from Australia, has been approved by the National Medical Products Administration (NMPA) in China, marking it as the 10th novel product supported by Lecheng’s real-world data. This Category III medical device is set to make a significant impact on the correction of…
-
CDE Considers Breakthrough Therapy Designation for Beijing Mabworks’ MIL162 and Amgen’s AMG 890
•
The Center for Drug Evaluation (CDE) website indicates that China-based Beijing Mabworks Biotech Co., Ltd’s MIL162 and US firm Amgen’s AMG 890 are on track to receive breakthrough therapy designation (BTD) awards in China. MIL162 is under development as a treatment for primary membranous nephropathy (pMN), while AMG 890 targets…
-
Fujian Cosunter Pharmaceutical’s COVID-19 Drug GST-HG171 Meets Primary Endpoint in Phase II/III Study
•
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that the pivotal Phase II/III regulatory clinical study for its Category 1 product, GST-HG171/ritonavir, in mild/moderate COVID-19 patients has been unblinded and has successfully reached its primary endpoint. Design and Results of the StudyThe multi-center, randomized, double-blind, placebo-controlled study aimed…
-
Boehringer Ingelheim’s Spevigo on Track for Priority Review for GPP Flare Prevention in China
•
Germany-based Boehringer Ingelheim’s (BI) interleukin-36 receptor (IL-36R)-targeted orphan drug, Spevigo (spesolimab), in subcutaneous injection form, is poised for priority review status in China. This recognition from the Center for Drug Evaluation (CDE) is attributed to its potential use in preventing flares in generalized pustular psoriasis (GPP), following the molecule’s earlier…
-
Bio-Thera Solutions’ PD-1 Inhibitor BAT1308 Approved for Cervical Cancer Clinical Trials in China
•
Bio-Thera Solutions Ltd (SHA: 688177) has announced that its programmed death-1 (PD-1) inhibitor, BAT1308, has been approved to enter clinical trials for the treatment of cervical cancer in China. The molecule will be assessed in combination with platinum chemotherapy and with or without bevacizumab, as per the Chinese firm’s announcement.…
-
Pfizer to Establish Smart Medical Innovation Center in Hangzhou’s Qiantang District
•
US pharmaceutical giant Pfizer (NSE: PFIZER) has announced a plan to establish a smart medical innovation center in the Qiantang district of Hangzhou city in China. This initiative aims to bolster the Chinese medical industry’s digital innovation capabilities and contribute to the advancement of healthcare solutions in the region. Empowering…
-
Medivir AB Receives Chinese Patent Approval for Liver Cancer Treatment Fostroxacitabine Bralpamide
•
Sweden-based Medivir AB (FRA: MVR0) has announced the approval of a patent in China for its fostroxacitabine bralpamide (fostrox) and its use in the treatment of liver cancer. The patent, which remains valid until 2035 with potential for extensions, is a significant milestone for Medivir, considering China’s large population of…
-
Shanghai Cell Therapy Group Partners with Nantong Federation for Comprehensive Health Services Platform
•
Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry and Commerce, aiming to leverage their respective advantageous resources to create a comprehensive medical service platform. The collaboration will provide a range of health services, including high-end medical care, cell health, early tumor screening, and…
-
Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has entered into a strategic partnership with compatriot firm Yoltech Therapeutics Co., Ltd. The collaboration aims to advance the development of gene editing products, mRNA drugs, and related services in both domestic and international markets. Focus…
-
Merck Appoints Marc Horn as China Unit President, Succeeding Allan Gabor
•
Germany-based Merck (NYSE: MRK) has announced the appointment of Marc Horn as its China unit president, effective as of January 1, 2024. Horn will take over from Allan Gabor, who is set to retire on December 31, 2023. In his new role, Horn will be responsible for formulating Merck’s development…
-
Sinocelltech Group Launches Biosimilar Version of AbbVie’s Humira in China
•
China-based Sinocelltech Group Ltd (SHA: 688520) has officially commercialized its biosimilar version of AbbVie’s (NYSE: ABBV) Humira (adalimumab), marking a significant milestone in the Chinese biosimilar market. The company has delivered the first batch of the biosimilar product, achieving commercialization in less than two weeks following regulatory approval. Humira’s Global…
-
Grand Pharmaceutical Initiates Phase II STARBURST Study for TLX250-CDx in Indication Expansion
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the indication expansion Phase II STARBURST study for its TLX250-CDx (89Zr-DFO-girentuximab). The imaging agent is licensed from Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) in a 2020 deal valued at up to USD 225 million. The 2020…
-
Novlead Biotech Secures RMB 100 Million in Series B+ Financing for Nitric Oxide Therapy Innovations
•
Novlead Biotech, a specialist in nitric oxide gas detection and treatment based in Nanjing, has successfully completed a Series B+ financing round, raising RMB 100 million (USD 14 million). The round was led by Costone Asset Management, with significant contributions from Guanghua Holding, JYTH Investment, Lilly Asia ventures, and 3E…
-
Guangdong Zhongsheng Pharmaceutical Plans to Raise RMB 600 Million via Private Placement
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) is poised to raise RMB 600 million (USD 84 million) through a private placement of 38,969,401 shares, priced at RMB 15.36 per share. This strategic move aims to bolster the company’s financial position and support its expansion plans. Focus on Core Business…
-
Shanghai Pharmaceuticals’ SPH3127 for Hypertension Gets MNPA Review Acceptance
•
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products Administration (MNPA) has accepted a market approval filing for its SPH3127, a Category 1 drug co-developed with Japan-based Mitsubishi Tanabe Pharma Corporation. The intended indication for this novel drug is hypertension. SPH3127: A Novel Oral…
